128 related articles for article (PubMed ID: 15278007)
21. Levosimendan but not norepinephrine improves microvascular oxygenation during experimental septic shock.
Fries M; Ince C; Rossaint R; Bleilevens C; Bickenbach J; Rex S; Mik EG
Crit Care Med; 2008 Jun; 36(6):1886-91. PubMed ID: 18496356
[TBL] [Abstract][Full Text] [Related]
22. Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of force-frequency and relaxation-frequency relationships.
Givertz MM; Andreou C; Conrad CH; Colucci WS
Circulation; 2007 Mar; 115(10):1218-24. PubMed ID: 17339544
[TBL] [Abstract][Full Text] [Related]
23. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction.
Fuhrmann JT; Schmeisser A; Schulze MR; Wunderlich C; Schoen SP; Rauwolf T; Weinbrenner C; Strasser RH
Crit Care Med; 2008 Aug; 36(8):2257-66. PubMed ID: 18664782
[TBL] [Abstract][Full Text] [Related]
24. Ca2+ sensitizer superior to catecholamine during myocardial stunning?
Meyer K; Klocke RC; Schipke JD; Gams E; Korbmacher B
Eur J Cardiothorac Surg; 2008 Aug; 34(2):326-31. PubMed ID: 18539040
[TBL] [Abstract][Full Text] [Related]
25. Levosimendan: beyond its simple inotropic effect in heart failure.
Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
[TBL] [Abstract][Full Text] [Related]
26. Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction.
De Luca L; Proietti P; Celotto A; Bucciarelli-Ducci C; Benedetti G; Di Roma A; Sardella G; Genuini I; Fedele F
Am Heart J; 2005 Sep; 150(3):563-8. PubMed ID: 16169341
[TBL] [Abstract][Full Text] [Related]
27. The vasodilatory effects of levosimendan on the human internal mammary artery.
Montes FR; Echeverri D; Buitrago L; Ramírez I; Giraldo JC; Maldonado JD; Umaña JP
Anesth Analg; 2006 Nov; 103(5):1094-8. PubMed ID: 17056938
[TBL] [Abstract][Full Text] [Related]
28. Utility of levosimendan, a new calcium sensitizing agent, in the treatment of cardiogenic shock due to myocardial stunning in patients with ST-elevation myocardial infarction: a series of cases.
García-González MJ; Domínguez-Rodríguez A; Ferrer-Hita JJ
J Clin Pharmacol; 2005 Jun; 45(6):704-8. PubMed ID: 15901754
[No Abstract] [Full Text] [Related]
29. Levosimendan may improve weaning outcomes in venoarterial ECMO patients.
Affronti A; di Bella I; Carino D; Ragni T
ASAIO J; 2013; 59(6):554-7. PubMed ID: 24172260
[TBL] [Abstract][Full Text] [Related]
30. Levosimendan improves right ventriculovascular coupling in a porcine model of right ventricular dysfunction.
Missant C; Rex S; Segers P; Wouters PF
Crit Care Med; 2007 Mar; 35(3):707-15. PubMed ID: 17255859
[TBL] [Abstract][Full Text] [Related]
31. The cardioprotective effects of levosimendan: preclinical and clinical evidence.
Pollesello P; Papp Z
J Cardiovasc Pharmacol; 2007 Sep; 50(3):257-63. PubMed ID: 17878752
[TBL] [Abstract][Full Text] [Related]
32. Timing of levosimendan in cardiac surgery.
Aksun M; Karahan N; Adanir T; Aran G; Yetkin U; Oztürk T; Sencan A; Ozgürbüz U; Gürbüz A
Anadolu Kardiyol Derg; 2009 Jun; 9(3):223-30. PubMed ID: 19520657
[TBL] [Abstract][Full Text] [Related]
33. Effects of levosimendan on the energy balance: preclinical and clinical evidence.
Nieminen MS; Pollesello P; Vajda G; Papp Z
J Cardiovasc Pharmacol; 2009 Apr; 53(4):302-10. PubMed ID: 19276987
[TBL] [Abstract][Full Text] [Related]
34. Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty.
Samimi-Fard S; García-González MJ; Domínguez-Rodríguez A; Abreu-González P
Int J Cardiol; 2008 Jul; 127(2):284-7. PubMed ID: 17643519
[TBL] [Abstract][Full Text] [Related]
35. Levosimendan reversing low output syndrome after heart transplantation.
Petäjä LM; Sipponen JT; Hämmäinen PJ; Eriksson HI; Salmenperä MT; Suojaranta-Ylinen RT
Ann Thorac Surg; 2006 Oct; 82(4):1529-31. PubMed ID: 16996977
[TBL] [Abstract][Full Text] [Related]
36. Role of levosimendan in sepsis and septic shock.
Pinto BB; Rehberg S; Ertmer C; Westphal M
Curr Opin Anaesthesiol; 2008 Apr; 21(2):168-77. PubMed ID: 18443483
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of a reduced cardiac output and the effects of milrinone and levosimendan in a model of infant cardiopulmonary bypass.
Stocker CF; Shekerdemian LS; Nørgaard MA; Brizard CP; Mynard JP; Horton SB; Penny DJ
Crit Care Med; 2007 Jan; 35(1):252-9. PubMed ID: 17133188
[TBL] [Abstract][Full Text] [Related]
38. The effects of levosimendan on myocardial function in ropivacaine toxicity in isolated guinea pig heart preparations.
Stehr SN; Christ T; Rasche B; Rasche S; Wettwer E; Deussen A; Ravens U; Koch T; Hübler M
Anesth Analg; 2007 Sep; 105(3):641-7. PubMed ID: 17717217
[TBL] [Abstract][Full Text] [Related]
39. Levosimendan in cardiac surgery: current best available evidence.
Raja SG; Rayen BS
Ann Thorac Surg; 2006 Apr; 81(4):1536-46. PubMed ID: 16564321
[TBL] [Abstract][Full Text] [Related]
40. Experiences of levosimendan as an inotropic agent in conjunction with passive containment surgery.
Bredin F; Franco-Cereceda A
Scand Cardiovasc J; 2007 Jun; 41(3):197-200. PubMed ID: 17487771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
